secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2026-08-13T20:07:03+00:00
Accession:  0001104659-26-095905
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Q2 net loss $11.7M; PRECISE-AD interim shows no ARIA-E, biomarker declines
--------------------------------------------------------------------------------

- Q2 2026 net loss $11.7M ($1.28/share) vs $10.1M ($7.26/share) in Q2 2025.
- Cash and short-term investments $53.4M at June 30, 2026, up from $6.1M at Dec 31, 2025; $70.1M net proceeds from Jan 2026 private placement.
- PRECISE-AD interim (136 patients): zero ARIA-E cases; 4.4% total ARIA (all mild ARIA-H); plasma pTau217 -15%, CSF MTBR-tau243 -13.3% in blinded pooled analysis.
- Expects unblinded 12-month topline data (cognitive outcomes) in Q1 2027; cash runway through 2027.
- Pipeline: PMN267 (TDP-43) and PMN442 (alpha-synuclein) advancing toward IND-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000110465926095905/0001104659-26-095905-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000110465926095905/pmn-20260813x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-095905

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer